Details

Autor(en) / Beteiligte

• Schneider, Edith
• Staffas, Anna
• Röhner, Linda
• Malmberg, Erik D
• Ashouri, Arghavan
• Krowiorz, Kathrin
• Pochert, Nicole
• Miller, Christina
• Wei, Stella Yuan
• Arabanian, Laleh
• Buske, Christian
• Döhner, Hartmut
• Bullinger, Lars
• Fogelstrand, Linda
• Heuser, Michael
• Döhner, Konstanze
• Xiang, Ping
• Ruschmann, Jens
• Petriv, Oleh I
• Heravi-Moussavi, Alireza
• Hansen, Carl L
• Hirst, Martin
• Humphries, R Keith
• Rouhi, Arefeh
• Palmqvist, Lars
• Kuchenbauer, Florian

Titel

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia

Ist Teil von

• Haematologica (Roma), 2018-02, Vol.103 (2), p.246

Ort / Verlag

Italy

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets of miR-155 have been identified, it is not clear how it contributes to the pathogenesis of acute myeloid leukemia. We found miR-155 to be a direct target of Meis1 in murine Hoxa9/Meis1 induced acute myeloid leukemia. The additional overexpression of miR-155 accelerated the formation of acute myeloid leukemia in Hoxa9 as well as in Hoxa9/Meis1 cells However, in the absence or following the removal of miR-155, leukemia onset and progression were unaffected. Although miR-155 accelerated growth and homing in addition to impairing differentiation, our data underscore the pathophysiological relevance of miR-155 as an accelerator rather than a driver of leukemogenesis. This further highlights the complexity of the oncogenic program of Meis1 to compensate for the loss of a potent oncogene such as miR-155. These findings are highly relevant to current and developing approaches for targeting miR-155 in acute myeloid leukemia.